

Copper(I) Iodide: A Catalyst for the Improved Synthesis of Aryl Propargyl Ethers

David Bell, Mark R. Davies, Graham R. Geen, Inderjit S. Mann*



SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, England

Fax +44(1279)622348

Received 28 November 1994

Copper(I) iodide catalyses the reaction between phenols and dialkylpropargyl chlorides to give aryl 1,1-dialkylpropargyl ethers **5a–k** and **7a–e** in good yields and purity. These ethers are important as precursors to the 2*H*-1-benzopyrans **8a–l** and **9a–e**.

There are many examples of biologically active compounds based on the benzopyran nucleus. Two of recent interest to us are the anti-hypertensive levcromakalim¹ (**1**), and BRL 55834² (**2**), an airways selective potassium channel activator for the treatment of asthma. Other potassium channel activators based on the benzopyran nucleus to have appeared recently are EMD 52692,³ SDZ PCO-400,⁴ Ro 31-6930,⁵ WAY 120491⁶ and EMD 57283.⁷ A feature common to all these compounds is the presence of a strongly electron-withdrawing substituent at position C-6 of the benzopyran ring, believed to be important for the presence of biological activity.^{8,9}




The syntheses of levcromakalim and BRL 55834 require efficient and high yielding preparations of their benzopyran precursors, 6-cyano-2,2-dimethyl-2*H*-1-benzopyran^{8,10,11} (**8a**) and 2,2-dimethyl-6-pentafluoroethyl-2*H*-1-benzopyran² (**8c**). Current preparations of 2*H*-1-benzopyrans having electron-withdrawing substituents generally give low to moderate yields of product^{8,11–13} and this prompted us to investigate improved procedures towards these compounds.

Many syntheses of 2*H*-1-benzopyrans are to be found in the literature.¹⁴ Condensations of phenols with α,β -unsaturated aldehydes¹⁵ or their acetal equivalents¹⁶ are generally only suitable for polyhydric phenols or monohydric phenols with electron-donating substituents. Other methods such as reactions of salicylaldehydes with acrylate esters^{17,18} or vinyl¹⁹ and allyl triphenylphosphonium salts²⁰ are generally low yielding, especially for 2,2-dimethyl-2*H*-1-benzopyrans, and suffer from lack of availability of the salicylaldehyde starting materials.

Of the methods available, synthesis of 2*H*-1-benzopyrans via Claisen rearrangement of propargyl ethers is well documented,^{21–23} and this approach was found to be the most suitable for our purposes. Aryl propargyl ethers are usually prepared by the reaction of phenols with a propargyl chloride in the presence of potassium carbonate and potassium iodide in acetone or DMF as solvent,^{22,23} although other base/solvent combinations⁸

and other methods²⁴ have also been used. However, the syntheses of aryl propargyl ethers from phenols having electron-withdrawing groups often give low yields by this method.⁸ We have now found that the addition of a catalytic amount of copper(I) iodide to the reaction provides ethers in high yield and purity, and that this new method is especially useful when reacting phenols having electron-withdrawing groups. They can then be cyclised in a suitable high boiling solvent such as *N,N*-diethylaniline,²¹ *o*-dichlorobenzene,^{8,25} or DMF²³ to the corresponding 2*H*-1-benzopyrans.

For the preparation of BRL 55834 we required 2,2-dimethyl-6-pentafluoroethyl-2*H*-1-benzopyran (**8c**), and the most efficient way of making this is to prepare 6-bromo^{13,17} or 6-iodo-2*H*-1-benzopyran²⁶ (**8e**, **8f**), and convert it to **8c** using known methodology.² Thus the reaction of 4-bromophenol with 3-chloro-3-methylbut-1-yne²⁷ (**4a**) in the presence of potassium carbonate and potassium iodide in DMF or *N*-methylpyrrolidin-2-one gave only a 35% yield of pure ether **5e**, after a 24–48 hour reaction time (Table 1). It was then discovered that the addition of catalytic quantities of copper(I) iodide (2 mol%) resulted in a much faster reaction, and gave a 74% distilled yield of ether **5e** of high purity after a reaction time of only 2 hours. Significantly, the use of greater than 5 mol% of catalyst was found to be detrimental to the reaction, resulting in lower yields of product. The reaction with 4-iodophenol was found to proceed well without copper(I) iodide giving a high yield of **5f** after 24 hours, but in the presence of the catalyst a much faster reaction was nevertheless obtained, and the reaction was complete within 2 hours. The 2*H*-1-benzopyrans **8e** and **8f** resulting from cyclisation of the corresponding ethers could then be converted to **8c** in good yield. Alternatively, we also prepared 4-pentafluoroethylphenol²⁸ (**3c**) and reacted this using the new method to obtain the product **5c** directly in high yield (Scheme 1).



Scheme 1

With the benefit of adding catalytic quantities of copper(I) iodide resulting in faster reaction rates and improved yields, we have evaluated a number of other phenols in this reaction (Table 1). The advantages of using copper(I) iodide are most pronounced in reactions involving

Table 1. Preparation of Aryl 1,1-Dimethylpropargyl Ethers **5a–k**


Substrate	Product	R ¹	Yield (%) Without CuI	Yield (%) With CuI	mp (°C) or bp (°C/mbar)	Lit. mp (°C) or bp (°C/mmHg)
3a	5a	4-CN	32	96	29.5–31 ^a	29–30.5 ²⁵
3b	5b	4-NO ₂	40	89	31–32.5 ^a	88–90/0.05 ²⁵
3c	5c	4-C ₂ F ₅		72	42–44/0.35	
3d	5d	4-Ac	55	85	93–95/0.35	120/1 ²⁹
3e	5e^b	4-Br	35	74	68–70/0.35	96–106/1 ³⁰
3f	5f	4-I	76	73	82–84/0.35	
3g	5g	4-Et		21	59–60/0.35	
3h	5h	4-OMe	13	26	63–66/0.35	74–75/0.35 ²²
3i	5i	4-H		40	36–37/0.35	49–50/1 ²²
3j	5j	3-CN		84	78–80/0.35	97–98/0.2 ⁸
3k	5k	2-CN		95	95–96/0.35	108–110/0.1 ⁸

^a Purified by distillation. Product crystallised on standing.

^b *N*-Methylpyrrolidin-2-one used as solvent.

phenols having electron-withdrawing substituents, such as 4-cyanophenol (**3a**) and 4-nitrophenol (**3b**) which gave yields of ethers **5a** and **5b** of 96 % and 89 % respectively after reaction times of 1 hour. Both these examples give significantly higher yields than the previously published procedures (**5a** and **5b** were obtained in yields of 69 %⁸ and 45 %³¹ respectively after reaction times of 4 days). Phenols lacking electron-withdrawing substituents were found not to be as efficient at reacting under these conditions, although other methods are available for preparing these compounds.^{22,23}

In order to examine further the scope of this reaction we were interested in preparing *2H*-1-benzopyrans with different 2-alkyl substituents by this method. Thus a series of dialkyl propargyl chlorides²⁷ (**6a–e**) was prepared and their reactions with 4-cyanophenol were evaluated (Scheme 2). Although the yields were not as good as those obtained using 3-chloro-3-methylbut-1-yne (**4a**), better yields were still obtained when copper(I) iodide was employed as a catalyst, even though in most cases unreacted phenol still remained. Even highly hindered substrates such as methyl-*tert*-butylpropargyl chloride (**6c**) and diisopropylpropargyl chloride (**6e**) gave reasonable yields of ethers (Table 2).

**Scheme 2**

During the course of preparation of this manuscript, another publication appeared detailing the preparation of aryl 1,1-dimethylpropargyl ethers catalysed by copper(I) chloride in acetonitrile containing 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).³² Contrary to the findings

in this paper we have found that the use of the acetate **4b**³³ (Scheme 1) also gives aryl 1,1-dimethylpropargyl ethers in high yield by our method. Thus reaction of **4b** with 4-cyanophenol under standard conditions afforded the corresponding ether **5a** in 84 % yield after distillation.

From a mechanistic viewpoint solvolysis of 3-chloro-3-methylbut-1-yne under basic conditions is believed to proceed via deprotonation of the terminal acetylenic proton, resulting in the formation of a zwitterionic and/or a carbenoid species, which then reacts with a nucleophile³⁴ (Scheme 3). A recent publication³⁵ has shown that Cu(I) salts also catalyse the amination of propargyl acetates and phosphates by the proposed intermediacy of a Cu acetylide species, and a similar mechanistic rationale could therefore be postulated for the reaction with phenols.

All propargyl ethers were cyclised to their corresponding *2H*-1-benzopyrans (Table 3) in DMF containing *N,N*-diethylaniline at 140–150 °C in moderate to high yields (Scheme 4).


Table 2. Preparation of Aryl 1,1-Dialkylpropargyl Ethers **5a** and **7a–e**

Chloride	Product	R ²	R ³	Without CuI Yield (%)	With CuI Yield (%)	mp (°C) or bp (°C/ mbar)
4a	5a	Me	Me	32	96	29.5–31
6a	7a ³⁰	Me	Et	16	100	86–88/0.35
6b	7b	Et	Et	18	91	97–100/0.35
6c	7c	Me	<i>t</i> -Bu	13	53	60–60.5 ^a
6d	7d	–(CH ₂) ₅ –		18	85	52–53 ^b
6e	7e	<i>i</i> -Pr	<i>i</i> -Pr	26	62	c


^a Recrystallised from hexane.

^b Recrystallised from 10 % EtOAc in hexane.

^c Material cyclises to the *2H*-1-benzopyran on attempted distillation.



Scheme 3



Scheme 4

We have demonstrated that for phenols having electron-withdrawing substituents that their reaction with dialkylpropargyl chlorides proceeds significantly faster in the presence of catalytic quantities of copper(I) iodide, resulting in much higher yields of aryl propargyl ethers.

^1H NMR spectra were recorded either on a Bruker AMX 400 spectrometer at 400 MHz, or on a Jeol GX 270 spectrometer at 270 MHz. Signals are quoted as δ ppm downfield from internal tetramethylsilane. ^{13}C NMR spectra were recorded on the same instruments at 100 MHz (Bruker), or 67.5 MHz (Jeol), chemical shifts were referenced to the deuterated solvent signals. Mass spectra were obtained on a Fisons VG Biotric Trio 2 spectrometer. HPLC analyses were using a Lichrosphere 60 RP-Select B 5 μm , 125 mm $\times$ 4 mm column eluting with solutions of acetonitrile/0.05 M potassium dihydrogen phosphate unbuffered; UV detection was employed at 235 nm. Melting points were obtained with a Mettler FP90 Thermosystem.

3-(4-Cyanophenoxy)-3-methylbut-1-yne (**5a**); Typical Procedure:

3-Chloro-3-methylbut-1-yne (**4a**) (4.1 g, 40 mmol) was added to a mixture of 4-cyanophenol (**3a**) (2.38 g, 20 mmol), 325 mesh K_2CO_3 (5.52 g, 40 mmol), KI (5.64 g, 34 mmol) and CuI (0.076 g, 0.4 mmol) in dry DMF (20 mL) under Ar, and the reaction stirred at 65°C until no further conversion to product took place when monitoring the reaction by HPLC. On cooling, water (150 mL) was added and the mixture extracted with hexane (2×150 mL). The combined hexane extracts were washed successively with 2 N NaOH (150 mL), 2 N HCl (150 mL), and water (100 mL), before drying (Na_2SO_4) and removal of solvent afforded crude **5a** as an oil. Vacuum distillation gave a 96% yield of purified **5a**.

When using the acetate **4b**, the reaction was carried out at 75°C for 6 h and gave an 84% yield of distilled **5a**.

6-Cyano-2,2-dimethyl-2H-1-benzopyran (**8a**); Typical Procedure:

A solution of the ether **5a** (1.85 g, 10 mmol) in dry DMF (10 mL) and *N,N*-diethylaniline (0.5 mL) was stirred under Ar at 140°C overnight. On cooling, the reaction mixture was poured into water (100 mL) and the mixture extracted with hexane (1×100 mL, 2×50 mL). The combined extracts were washed successively with 2 N NaOH (2×50 mL), 2 N HCl (2×50 mL) and water (50 mL), before drying (Na_2SO_4) and removal of solvent to afford crude **8a** as a yellow oil (1.70 g, 92%). This was recrystallised from hexane to afford a 67% yield of pure **8a**.

Table 3. Cyclisation of Arylpropargyl Ethers **5a-k** and **7a-e** to 2H-1-Benzopyrans **8a-l** and **9a-e**

Substrate	Product	R ¹	R ²	R ³	Yield (%)	mp (°C) or bp (°C/mbar)	Lit. mp (°C) or bp (°C/mmHg)
5a	8a	6-CN	Me	Me	67	48–49.5 ^a	36–37 ²⁵
5b	8b	6-NO ₂	Me	Me	74	71.5–72.5 ^b	71–72 ²⁵
5c	8c	6-C ₂ F ₅	Me	Me	84	55–57/0.35	62/0.3 ²
5d	8d	6-Ac	Me	Me	84	98–100/0.35	135–136/4 ³⁶
5e	8e	6-Br	Me	Me	73	83–84/0.35	143–146/19 ¹⁷
5f	8f	6-I	Me	Me	83	91–93/0.35	see ref. 26
5g	8g	6-Et	Me	Me	70	63–65/0.35	
5h	8h	6-OMe	Me	Me	69	71–73/0.35	132–136/15 ²²
5i	8i	6-H	Me	Me	67	42–45/0.35	79–80/2.5 ²²
5j	8j	5-CN	Me	Me	51 ^d	83–85/0.35	77–80/0.5 ⁸
5j	8k	7-CN	Me	Me	28 ^d	48–49 ^c	see ref. 8
5k	8l	8-CN	Me	Me	81	106–8/0.35	108–110/0.6 ⁸
7a	9a	6-CN	Me	Et	90	104–7/0.35	
7b	9b	6-CN	Et	Et	88	108–12/0.35	see ref. 37
7c	9c	6-CN	Me	<i>t</i> -Bu	50	58.5 ^b	
7d	9d	6-CN	–(CH ₂) ₅ –		51	94.5–95.5 ^b	94–95 ³
7e	9e	6-CN	<i>i</i> -Pr	<i>i</i> -Pr	57	77–77.5 ^b	

^a Purified by distillation, product solidified on standing.

^b Recrystallised from hexane.

^c Purified by chromatography.

^d Obtained as a 51 : 28 mixture of 5-CN : 7-CN substituted products.

Table 4. ^1H and ^{13}C NMR Data for Aryl Propargyl Ethers **5a–k** and **7a–e**

Product	^1H NMR (CDCl_3) δ	^{13}C NMR (CDCl_3) δ , J (Hz)
5a	1.70 (s, 6H, $2 \times \text{CH}_3$), 2.65 (s, 1H, CCH), 7.28 (m, 2H, H-2,6), 7.57 (m, 2H, H-3,5)	29.5 ($2 \times \text{CH}_3$), 72.7 [$\text{C}(\text{CH}_3)_2$], 75.2 (CCH), 84.7 (CCH), 105.2 (C-4), 119.1 (CN), 120.0 (C-2,6), 133.4 (C-3,5), 159.4 (C-1)
5b	1.73 (s, 6H, $2 \times \text{CH}_3$), 2.68 (s, 1H, CCH), 7.30 (m, 2H, H-2,6), 8.18 (m, 2H, H-3,5)	29.5 ($2 \times \text{CH}_3$), 73.0 [$\text{C}(\text{CH}_3)_2$], 75.5 (CCH), 84.5 (CCH), 119.0 (C-2,6), 125.2 (C-3,5), 142.2 (C-4), 161.3 (C-1)
5c	1.69 (s, 6H, $2 \times \text{CH}_3$), 2.61 (s, 1H, CCH), 7.31 (m, 2H, H-2,6), 7.50 (m, 2H, H-3,5)	29.6 ($2 \times \text{CH}_3$), 72.5 [$\text{C}(\text{CH}_3)_2$], 74.8 (CCH), 85.3 (CCH), 113.7 (tq, $J = 253$, 38, CF_2), 119.3 (qt, $J = 286$, 40, CF_3), 120.0 (C-2,6), 122.1 (t, $J = 24$, C-4), 127.6 (t, $J = 6$, C-3,5), 158.8 (C-1)
5d	1.71 (s, 6H, $2 \times \text{CH}_3$), 2.58 (s, 3H, CH_3CO), 2.67 (s, 1H, CCH), 7.29 (m, 2H, H-2,6), 7.92 (m, 2H, H-3,5)	26.4 (CH_3CO), 29.6 ($2 \times \text{CH}_3$), 72.4 [$\text{C}(\text{CH}_3)_2$], 74.8 (CCH), 85.2 (CCH), 119.3 (C-2,6), 129.9 (C-3,5), 131.3 (C-4), 160.0 (C-1), 196.9 (CH_3CO)
5e	1.64 (s, 6H, $2 \times \text{CH}_3$), 2.58 (s, 1H, CCH), 7.09 (m, 2H, H-2,6), 7.38 (m, 2H, H-3,5)	29.5 ($2 \times \text{CH}_3$), 72.8 [$\text{C}(\text{CH}_3)_2$], 74.3 (CCH), 85.7 (CCH), 115.7 (C-4), 123.3 (C-2,6), 131.9 (C-3,5), 154.7 (C-1)
5f	1.63 (s, 6H, $2 \times \text{CH}_3$), 2.57 (s, 1H, CCH), 6.97 (m, 2H, H-2,6), 7.56 (m, 2H, H-3,5)	29.5 ($2 \times \text{CH}_3$), 72.6 [$\text{C}(\text{CH}_3)_2$], 74.3 (CCH), 85.6 (CCH), 86.0 (C-4), 123.5 (C-2,6), 137.9 (C-3,5), 155.5 (C-1)
5g	1.22 (t, 3H, CH_2CH_3), 1.63 (s, 6H, $2 \times \text{CH}_3$), 2.53 (s, 1H, CCH), 2.60 (q, 2H, CH_2CH_3), 7.10 (m, 4H, Ar)	15.6 (CH_2CH_3), 28.1 (CH_2CH_3), 29.6 [$\text{C}(\text{CH}_3)_2$], 72.4 [$\text{C}(\text{CH}_3)_2$], 73.6 (CCH), 86.4 (CCH), 121.7 (C-2,6), 128.1 (C-3,5), 138.8 (C-4), 153.4 (C-1)
5h	1.59 (s, 6H, $2 \times \text{CH}_3$), 2.51 (s, 1H, CCH), 3.77 (s, 3H, OCH_3), 6.80 (m, 2H, H-3,5), 7.12 (m, 2H, H-2,6)	29.5 ($2 \times \text{CH}_3$), 55.5 (OCH_3), 73.0 [$\text{C}(\text{CH}_3)_2$], 73.6 (CCH), 86.4 (CCH), 113.9 (C-3,5), 123.7 (C-2,6), 148.9 (C-1), 155.8 (C-4)
5i	1.63 (s, 6H, $2 \times \text{CH}_3$), 2.53 (s, 1H, CCH), 7.03 (m, 1H, H-4), 7.20 (m, 2H, H-2,6), 7.26 (m, 2H, H-3,5)	29.6 ($2 \times \text{CH}_3$), 72.3 [$\text{C}(\text{CH}_3)_2$], 73.8 (CCH), 86.2 (CCH), 121.5 (C-2,6), 122.9 (C-4), 128.9 (C-3,5), 155.6 (C-1)
5j	1.66 (s, 6H, $2 \times \text{CH}_3$), 2.64 (s, 1H, CCH), 7.34 (dd, 1H, H-4), 7.37 (t, 1H, H-5), 7.42 (dd, 1H, H-6), 7.51 (d, 1H, H-2)	29.7 ($2 \times \text{CH}_3$), 73.4 [$\text{C}(\text{CH}_3)_2$], 75.4 (CCH), 85.2 (CCH), 113.0 (C-3), 118.9 (CN), 124.3 (C-2), 126.0 (C-4), 126.5 (C-6), 130.1 (C-5), 156.1 (C-1)
5k	1.75 (s, 6H, $2 \times \text{CH}_3$), 2.66 (s, 1H, CCH), 7.08 (t, 1H, H-4), 7.50 (t, 1H, H-5), 7.56 (d, 1H, H-3), 7.65 (d, 1H, H-6)	29.7 ($2 \times \text{CH}_3$), 74.5 [$\text{C}(\text{CH}_3)_2$], 75.5 (CCH), 85.1 (CCH), 106.4 (C-2), 117.0 (CN), 119.8 (C-6), 122.7 (C-4), 133.6 (C-3), 133.8 (C-5), 158.2 (C-1)
7a	1.10 (t, 3H, CH_2CH_3), 1.62 (s, 3H, CH_3), 1.95 (m, 2H, CH_2CH_3), 2.67 (s, 1H, CCH), 7.28 (m, 2H, H-2,6), 7.56 (m, 2H, H-3,5)	8.5 (CH_2CH_3), 26.1 (CH_3), 35.4 (CH_2), 76.3 (CCH and $[\text{C}(\text{Et})(\text{Me})]$), 83.7 (CCH), 105.0 (C-4), 119.1 (CN), 120.0 (C-2,6), 133.3 (C-3,5), 159.5 (C-1)
7b	1.03 (t, 6H, $2 \times \text{CH}_3$), 1.95 (m, 4H, $2 \times \text{CH}_2$), 2.68 (s, 1H, CCH), 7.28 (m, 2H, H-2,6), 7.55 (m, 2H, H-3,5)	8.2 ($2 \times \text{CH}_3$), 31.3 ($2 \times \text{CH}_2$), 77.4 (CCH), 80.0 [$\text{C}(\text{Et})_2$], 83.1 (CCH), 105.0 (C-4), 119.2 (CN), 120.1 (C-2,6), 133.4 (C-3,5), 159.7 (C-1)
7c	1.16 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.54 (s, 3H, CH_3), 2.64 (s, 1H, CCH), 7.29 (m, 2H, H-2,6), 7.56 (m, 2H, H-3,5)	20.8 (CH_3), 25.1 [$\text{C}(\text{CH}_3)_3$], 39.6 [$\text{C}(\text{CH}_3)_3$], 77.1 (CCH), 82.0 [$\text{C}(\text{Me})(t\text{-Bu})$], 83.5 (CCH), 105.3 (C-4), 119.2 (CN), 120.9 (C-2,6), 133.3 (C-3,5), 159.9 (C-1)
7d	1.4–2.1 (m, 10H, $5 \times \text{CH}_2$), 2.72 (s, 1H, CCH), 7.31 (m, 2H, H-2,6), 7.56 (m, 2H, H-3,5)	22.4 ($2 \times \text{CH}_2$), 25.0 (CH_2), 37.5 ($2 \times \text{CH}_2$), 76.1 [$\text{C}(\text{CH}_2)_2$], 77.0 (CCH), 84.0 (CCH), 105.0 (C-4), 119.2 (CN), 120.1 (C-2,6), 133.4 (C-3,5), 159.3 (C-1)
7e	1.06 (d, 6H, $2 \times \text{CH}_3$), 1.11 (d, 6H, $2 \times \text{CH}_3$), 2.28 (spt, 2H, $2 \times \text{CH}$), 2.75 (s, 1H, CCH), 7.30 (m, 2H, H-2,6), 7.52 (m, 2H, H-3,5)	17.8 ($2 \times \text{CH}_3$), 18.6 ($2 \times \text{CH}_3$), 36.0 ($2 \times \text{CH}$), 80.9 (CCH), 81.1 (CCH), 88.5 [$\text{C}(i\text{-Pr})_2$], 105.2 (C-4), 119.5 (CN), 121.8 (C-2,6), 133.2 (C-3,5), 161.7 (C-1)

Table 5. ^1H and ^{13}C NMR Data for 2*H*-1-Benzopyrans **8a–l** and **9a–e**

Product ^a	^1H NMR (CDCl_3) δ , J (Hz)	^{13}C NMR (CDCl_3) δ , J (Hz)
8a	1.45 (s, 6H, $2 \times \text{CH}_3$), 5.70 (d, 1H, $J = 10.0$, H-3), 6.28 (d, 1H, $J = 10.0$, H-4), 6.79 (d, 1H, $J = 8.4$, H-8), 7.24 (d, 1H, $J = 2.1$, H-5), 7.37 (dd, 1H, $J = 2.1$, 8.4, H-7)	28.4 ($2 \times \text{CH}_3$), 77.8 (C-2), 103.8 (C-6), 117.2 (C-8), 119.2 (CN), 120.6 (C-4), 121.7 (C-4a), 130.1 (C-5), 132.2 (C-3), 133.3 (C-7), 156.8 (C-8a)
8b	1.48 (s, 6H, $2 \times \text{CH}_3$), 5.75 (d, 1H, $J = 10.0$, H-3), 6.35 (d, 1H, $J = 10.0$, H-4), 6.81 (d, 1H, $J = 8.9$, H-8), 7.89 (d, 1H, $J = 2.8$, H-5), 8.02 (dd, 1H, $J = 2.8$, 8.9, H-7)	28.5 ($2 \times \text{CH}_3$), 78.5 (C-2), 116.5 (C-8), 120.8 (C-4, 4a), 122.0 (C-5), 125.2 (C-7), 132.3 (C-3), 141.4 (C-6), 158.7 (C-8a)
8c	1.45 (s, 6H, $2 \times \text{CH}_3$), 5.67 (d, 1H, $J = 9.9$, H-3), 6.32 (d, 1H, $J = 9.9$, H-4), 6.83 (d, 1H, $J = 8.4$, H-8), 7.17 (d, 1H, $J = 2.2$, H-5), 7.30 (dd, 1H, $J = 2.2$, 8.4, H-7)	28.3 ($2 \times \text{CH}_3$), 77.3 (C-2), 113.6 (tq, $J = 38$, 253, CF_2), 116.6 (C-8), 119.3 (qt, $J = 40$, 286, CF_3), 120.7 (t, $J = 24$, C-6), 121.3 (C-4a), 121.4 (C-4), 124.6 (t, $J = 6.2$, C-5), 127.4 (t, $J = 6.2$, C-7), 131.8 (C-3), 156.0 (C-8a)
8d	1.45 (s, 6H, $2 \times \text{CH}_3$), 2.52 (s, 3H, COCH_3), 5.66 (d, 1H, $J = 9.9$, H-3), 6.34 (d, 1H, $J = 9.9$, H-4), 6.78 (d, 1H, $J = 8.4$, H-8), 7.61 (d, 1H, $J = 2.2$, H-5), 7.74 (dd, 1H, $J = 2.2$, 8.4, H-7)	26.3 (CH_3), 28.4 ($2 \times \text{CH}_3$), 77.5 (C-2), 116.1 (C-8), 120.7 (C-4a), 121.7 (C-4), 126.9 (C-5), 130.2 (C-7), 130.4 (C-6), 131.2 (C-3), 157.4 (C-8a), 196.7 (CO)

Table 5. (continued)

Product ^a	¹ H NMR (CDCl ₃) δ, J (Hz)	¹³ C NMR (CDCl ₃) δ, J (Hz)
8e	1.41 (s, 6H, 2 × CH ₃), 5.62 (d, 1H, J = 9.8, H-3), 6.23 (d, 1H, J = 9.8, H-4), 6.64 (d, 1H, J = 8.5, H-8), 7.07 (d, 1H, J = 2.4, H-5), 7.17 (dd, 1H, J = 2.4, 8.5, H-7)	28.2 (2 × CH ₃), 76.8 (C-2), 112.8 (C-6), 118.3 (C-8), 121.6 (C-4), 123.4 (C-4a), 129.0 (C-5), 131.8 (C-7), 132.2 (C-3), 152.3 (C-8a)
8f	1.40 (s, 6H, 2 × CH ₃), 5.60 (d, 1H, J = 9.8, H-3), 6.21 (d, 1H, J = 9.8, H-4), 6.53 (d, 1H, J = 8.4, H-8), 7.25 (d, 1H, J = 2.2, H-5), 7.35 (dd, 1H, J = 2.2, 8.4, H-7)	28.0 (2 × CH ₃), 76.5 (C-2), 82.4 (C-6), 118.6 (C-8), 121.1 (C-4), 123.7 (C-4a), 131.7 (C-3), 134.6 (C-5), 137.6 (C-7), 152.8 (C-8a)
8g	1.19 (t, 3H), 1.41 (s, 6H, 2 × CH ₃), 2.54 (q, 2H, CH ₂), 5.58 (d, 1H, J = 9.7, H-3), 6.28 (d, 1H, J = 9.7, H-4), 6.69 (d, 1H, J = 8.2, H-8), 6.79 (d, 1H, J = 2.1, H-5), 6.92 (dd, 1H, J = 2.1, 8.2, H-7)	16.0 (CH ₃), 28.2 (2 × CH ₃), 28.3 (CH ₂), 76.2 (C-2), 116.3 (C-8), 121.3 (C-4a), 122.7 (C-4), 125.8 (C-5), 128.6 (C-7), 131.0 (C-3), 136.7 (C-6), 151.1 (C-8a)
8h	1.40 (s, 6H, 2 × CH ₃), 3.74 (s, 3H, OCH ₃), 5.62 (d, 1H, J = 9.8, H-3), 6.27 (d, 1H, J = 9.8, H-4), 6.54 (d, 1H, J = 2.8, H-5), 6.65 (dd, 1H, J = 2.8, 8.7, H-7), 6.70 (d, 1H, J = 8.7, H-8)	27.9 (2 × CH ₃), 56.0 (OCH ₃), 76.0 (C-2), 111.8 (C-5), 114.5 (C-7), 117.1 (C-8), 122.2 (C-4a), 122.7 (C-4), 132.0 (C-3), 147.0 (C-8a), 154.0 (C-6)
8i	1.42 (s, 6H, 2 × CH ₃), 5.58 (d, 1H, J = 9.8, H-3), 6.30 (d, 1H, J = 9.8, H-4), 6.76 (d, 1H, J = 7.8, H-8), 6.83 (dt, 1H, J = 1.2, 7.5, H-6), 6.95 (dd, 1H, J = 1.6, 7.4, H-5), 7.08 (dt, 1H, J = 1.6, 7.8, H-7)	28.0 (2 × CH ₃), 76.1 (C-2), 116.3 (C-8), 120.7 (C-6), 121.3 (C-4a), 122.3 (C-4), 126.3 (C-5), 129.0 (C-7), 130.7 (C-3), 152.9 (C-8a)
8j	1.45 (s, 6H, 2 × CH ₃), 5.83 (d, 1H, J = 10.0, H-3), 6.65 (d, 1H, J = 10.0, H-4), 6.96 (dd, 1H, J = 2.4, 8.0, H-8), 7.13 (m, 2H, H-6, 7)	27.9 (2 × CH ₃), 77.0 (C-2), 108.9 (C-5), 117.2 (CN), 118.9 (C-4), 121.0 (C-8), 123.8 (C-4a), 124.6 (C-6), 129.2 (C-7), 134.2 (C-3), 153.2 (C-8a)
8k	1.45 (s, 6H, 2 × CH ₃), 5.77 (d, 1H, J = 10.0, H-3), 6.32 (d, 1H, J = 10.0, H-4), 7.00 (d, 1H, J = 1.6, H-8), 7.01 (d, 1H, J = 8.4, H-5), 7.11 (dd, 1H, J = 1.6, 8.4, H-6)	28.1 (2 × CH ₃), 77.1 (C-2), 111.9 (C-7), 118.9 (CN), 119.6 (C-8), 121.2 (C-4), 124.7 (C-6), 125.6 (C-4a), 126.7 (C-5), 134.1 (C-3), 153.1 (C-8a)
8l	1.50 (s, 6H, 2 × CH ₃), 5.70 (d, 1H, J = 10.0, H-3), 6.30 (d, 1H, J = 10.0, H-4), 6.86 (t, 1H, J = 7.9, H-6), 7.14 (dd, 1H, J = 1.7, 7.5, H-5), 7.32 (dd, 1H, J = 1.7, 7.9, H-7)	28.3 (2 × CH ₃), 78.6 (C-2), 100.5 (C-8), 116.3 (CN), 120.7 (C-6), 120.8 (C-4), 121.8 (C-4a), 130.3 (C-5), 132.1 (C-3, 7), 155.7 (C-8a)
9a	0.95 (t, 3H, CH ₂ CH ₃), 1.40 (s, 3H, CH ₃), 1.72 (m, 2H, CH ₂ CH ₃), 5.63 (d, 1H, J = 10.0, H-3), 6.33 (d, 1H, J = 10.0, H-4), 6.78 (1H, d, J = 8.3, H-8), 7.22 (d, 1H, J = 2.1, H-5), 7.36 (dd, 1H, J = 2.1, 8.3, H-7)	8.1 (CH ₂ CH ₃), 26.7 (CH ₃), 34.5 (CH ₂), 80.7 (C-2), 103.5 (C-6), 116.9 (C-8), 119.3 (CN), 121.4 (C-4), 121.6 (C-4a), 130.1 (C-5), 131.0 (C-3), 133.3 (C-7), 157.3 (C-8a)
9b	0.93 (t, 6H, 2 × CH ₃), 1.70 (m, 4H, 2 × CH ₂), 5.54 (d, 1H, J = 10.2, H-3), 6.39 (d, 1H, J = 10.2, H-4), 6.77 (d, 1H, J = 8.4, H-8), 7.20 (d, 1H, J = 2.1, H-5), 7.34 (dd, 1H, J = 2.1, 8.4, H-7)	7.9 (2 × CH ₃), 33.2 (CH ₂), 83.9 (C-2), 103.2 (C-6), 116.4 (C-8), 119.3 (CN), 121.5 (C-4a), 122.4 (C-4), 129.5 (C-3), 130.1 (C-5), 133.4 (C-7), 158.1 (C-8a)
9c	1.02 (s, 9H, 3 × CH ₃), 1.37 (s, 3H, CH ₃), 5.80 (d, 1H, J = 10.4, H-3), 6.32 (d, 1H, J = 10.4, H-4), 6.75 (d, 1H, J = 8.4, H-8), 7.19 (d, 1H, J = 2.0, H-5), 7.35 (dd, 1H, J = 2.0, 8.4, H-7)	22.7 (CH ₃), 24.9 [C(CH ₃) ₃], 39.2 [C(CH ₃) ₃], 85.2 (C-2), 103.1 (C-6), 116.5 (C-8), 119.4 (CN), 121.2 (C-4a), 129.0 (C-3), 130.0 (C-5), 133.4 (C-7), 157.7 (C-8a)
9d	1.35 (m, 2H, CH ₂), 1.56 (m, 4H, 2 × CH ₂), 1.73 (m, 2H, CH ₂), 1.92 (m, 2H, CH ₂), 5.73 (d, 1H, J = 10.0, H-3), 6.29 (d, 1H, J = 10.0, H-4), 6.84 (d, 1H, J = 8.4, H-8), 7.23 (d, 1H, J = 2.0, H-5), 7.37 (dd, 1H, J = 2.0, 8.4, H-7)	21.1 (2 × CH ₂), 25.1 (CH ₂), 36.3 (2 × CH ₂), 78.5 (C-2), 103.8 (C-6), 117.3 (C-8), 119.3 (CN), 121.1 (C-4), 122.6 (C-4a), 130.1 (C-5), 132.0 (C-3), 133.3 (C-7), 156.8 (C-8a)
9e	0.92 (d, 6H, 2 × CH ₃), 0.98 (d, 6H, 2 × CH ₃), 2.01 (spt, 2H, 2 × CH), 5.46 (d, 1H, J = 10.4, H-3), 6.43 (d, 1H, J = 10.4, H-4), 6.71 (d, 1H, J = 8.5, H-8), 7.14 (d, 1H, J = 1.9, H-5), 7.32 (dd, 1H, J = 1.9, 8.5, H-7)	16.2 (2 × CH ₃), 16.9 (2 × CH ₃), 35.4 (2 × CH), 88.7 (C-2), 102.6 (C-6), 115.4 (C-8), 119.4 (CN), 120.9 (C-4a), 123.2 (C-4), 125.8 (C-3), 130.2 (C-5), 133.5 (C-7), 159.2 (C-8a)

^a Satisfactory microanalyses were obtained for all new compounds: C ± 0.3, H ± 0.3.

We would like to thank Peter M. Kinney and Frances J. L. Finney for experimental assistance, and Eleanor A. Crowe and Ute B. Gerhardt for NMR analysis.

- (1) Ashwood, V. A.; Buckingham, R. E.; Cassidy, F.; Evans, J. M.; Faruk, E. A.; Hamilton, T. C.; Nash, D. J.; Stemp, G.; Willcocks, K. *J. Med. Chem.* **1986**, 29, 2194.
- (2) Buckle, D. R.; Eggleston, D. S.; Pinto, I. L.; Smith, D. G.; Tedder, J. M. *Biomed. Chem. Lett.* **1992**, 2, 1161.
- (3) Bergmann, R.; Gericke, R. *J. Med. Chem.* **1990**, 33, 492.
- (4) Fozard, J. R.; Menninger, K.; Cook, N. S.; Blarer, S.; Quast, U. *Br. J. Pharmacol.* **1990**, 99, 6P.
- (5) Paciorek, P. M.; Burden, D. T.; Burke, Y. M.; Cowlrick, I. S.; Perkins, R. S.; Taylor, J. C.; Waterfall, J. F. *J. Cardiovasc. Pharmacol.* **1990**, 15, 188.
- (6) Morin, M. E.; Wojdan, A.; Oshiro, G.; Colatsky, T.; Quagliato, D. *FASEB J.* **1990**, 4, A746.
- (7) Bergmann, R.; Eiermann, V.; Gericke, R. *J. Med. Chem.* **1990**, 33, 2759.
- (8) Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Watts, E. A. *J. Med. Chem.* **1983**, 26, 1582.
- (9) Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Showell, G. A. *J. Med. Chem.* **1984**, 27, 1127.
- (10) Evans, J. M.; Buckingham, R. E.; Willcocks, K. Eur. Patent 076075, 1983; *Chem. Abstr.* **1983**, 99, 88053.
- (11) Timar, T.; Eszenyi, T.; Sebok, P.; Galamb, V.; Fazekas, J.; Istvan, T.; Kovach, E.; Nagy, E. Eur. Patent 409651, 1991; *Chem. Abstr.* **1991**, 114, 143146.
- (12) Burrell, G.; Cassidy, F.; Evans, J. M.; Lightowler, D.; Stemp, G. *J. Med. Chem.* **1990**, 33, 3023.
- (13) Buckle, D. R.; Arch, J. R. S.; Fenwick, A. E.; Houge-Frydrych, C. S. V.; Pinto, I. L.; Smith, D. G.; Taylor, S. G.; Tedder, J. M. *J. Med. Chem.* **1990**, 33, 3028.

- (14) Hepworth, J. D. In *Comprehensive Heterocyclic Chemistry*; Vol. 3, Boulton, A. J.; McKillop, A. Eds.; Pergamon: Oxford, 1984; p 737.
Schweizer, E. E.; Meeder-Nycz, D. In *The Chemistry of Heterocyclic Compounds*; Vol 31, Ellis, G. P. Ed.; Wiley: London, 1977; p 11.
Merlini, L. *Adv. Heterocycl. Chem.* **1975**, *18*, 159.
- (15) Tiabi, M.; Zamarlik, H. *Tetrahedron Lett.* **1991**, *32*, 7251.
Bandaranayake, W. M.; Crombie, L.; Whiting, D. A. *J. Chem. Soc. (C)*, **1971**, 804.
Sartori, G.; Casiraghi, G.; Bolzoni, L.; Casnati, G. *J. Org. Chem.* **1979**, *44*, 803.
- (16) Bandaranayake, W. M.; Crombie, L.; Whiting, D. A. *J. Chem. Soc. (C)*, **1971**, 811.
Clarke, D. G.; Crombie, L.; Whiting, D. A. *J. Chem. Soc., Perkin Trans. 1*, **1974**, 1007.
Barton, D. H. R.; Donnelly, D. M. X.; Finet, J.-P.; Guiry, P. J. *Tetrahedron Lett.* **1990**, *31*, 7449.
- (17) Kawase, Y.; Yamaguchi, S.; Horita, H.; Takeno, J.; Kameyama, H. *Bull. Chem. Soc. Jpn.* **1982**, *55*, 1153.
- (18) Yamaguchi, S.; Saitoh, T.; Kamiyuzawa, M.; Enomoto, H.; Kawase, Y. *J. Heterocycl. Chem.* **1992**, *29*, 755.
- (19) Schweizer, E. E. *J. Am. Chem. Soc.* **1964**, *86*, 2744.
Schweizer, E. E.; Liehr, J.; Monaco, D. J. *J. Org. Chem.* **1968**, *33*, 2416.
- (20) Schweizer, E. E.; Shaffer, E. T.; Hughes, C. T.; Berninger, C. J. *J. Org. Chem.* **1966**, *31*, 2907.
Narasimhan, N. S.; Paradkar, M. V.; Gokhale, A. M. *Tetrahedron Lett.* **1970**, *11*, 1665.
- (21) Iwai, I.; Ide, J. *Chem. Pharm. Bull.* **1962**, *10*, 926.
Iwai, I.; Ide, J. *Chem. Pharm. Bull.* **1963**, *11*, 1042.
Anderson, W. K.; LaVoie, E. J. *J. Org. Chem.* **1973**, *38*, 3832.
Anderson, W. K.; LaVoie, E. J.; Whitkop, P. G. *J. Org. Chem.* **1974**, *39*, 881.
Brown, P. E.; Lewis, R. A. *J. Chem. Soc., Perkin Trans. 1*, **1992**, 573.
Zsindley, J.; Schmid, H. *Helv. Chim. Acta* **1968**, *51*, 1510.
- Pomeranz, U. K.; Hansen, H. J.; Schmid, H. *Helv. Chim. Acta* **1973**, *56*, 2981.
- (22) Hlubucek, J.; Ritchie, E.; Taylor, W. C. *Tetrahedron Lett.* **1969**, 1369.
Hlubucek, J.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1971**, *24*, 2347.
- (23) Hlubucek, J.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1970**, *23*, 1881.
- (24) Subramanian, R. S.; Balasubramanian, K. K. *Synth. Commun.* **1989**, *19*, 1255.
Subramanian, R. S.; Balasubramanian, K. K. *Tetrahedron Lett.* **1989**, *30*, 2297.
Subramanian, R. S.; Balasubramanian, K. K. *Tetrahedron Lett.* **1988**, *29*, 6797.
- (25) Harfenist, M.; Thom, E. *J. Org. Chem.* **1972**, *37*, 841.
- (26) Soll, R. M.; Dollings, P. J. U.S. Patent 4908378, 1990, *Chem. Abstr.* **1990**, *113*, 115088.
- (27) Hennion, G. F.; Boisselle, A. P. *J. Org. Chem.* **1961**, *26*, 725.
- (28) Umemoto, T.; Miyano, O. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 3361.
- (29) Bohlmann, F.; Bühmann, U. *Chem. Ber.* **1972**, *105*, 863.
- (30) Attwood, M. R.; Jones, P. S.; Redshaw, S. Eur. Patent 298452, 1989, *Chem. Abstr.* **1989**, *110*, 192654.
- (31) Connors, S. P.; Dennis, P. D.; Gill, E. W.; Terrar, D. A. *J. Med. Chem.* **1991**, *34*, 1570.
- (32) Godfrey Jr., J. D.; Mueller, R. H.; Sedergran, T. C.; Soundararajan, N.; Colandrea, V. J. *Tetrahedron Lett.* **1994**, *35*, 6405.
- (33) Hennion, G. F.; Schroeder, W. A.; Lu, R. P.; Scanlon, W. B. *J. Org. Chem.* **1956**, *21*, 1142.
- (34) Hennion, G. F.; Nelson, K. W. *J. Am. Chem. Soc.* **1957**, *79*, 2142.
Shiner Jr., V. J.; Wilson, J. W. *J. Am. Chem. Soc.* **1962**, *84*, 2402.
- (35) Imada, Y.; Yuasa, M.; Nakamura, I.; Murahashi, S.-I. *J. Org. Chem.* **1994**, *59*, 2282.
- (36) Naidhu, M. V.; Krishna Rao, G. S. *Synthesis* **1979**, 144.
- (37) Shiokawa, Y.; Takimoto, K.; Takenaka, K.; Kato, T. Eur. Patent 344747, 1989, *Chem. Abstr.* **1990**, *113*, 6361.